Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-07
2005-06-07
Mckane, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S111000
Reexamination Certificate
active
06903109
ABSTRACT:
This invention provides novel arylindenopyridines of the formula:and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing Adensine A2a receptors or reducing PDE activity in appropriate cells. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.
REFERENCES:
patent: 6063788 (2000-05-01), Brandes et al.
patent: 0825185 (1998-02-01), None
patent: 0825185 (1998-02-01), None
patent: 139556 (2001-05-01), None
patent: WO 93 08167 (1993-04-01), None
patent: WO 94/09002 (1994-04-01), None
patent: WO 99/03846 (1999-01-01), None
patent: WO 00/42019 (2000-07-01), None
patent: WO 00/68230 (2000-11-01), None
patent: WO 01/21621 (2001-03-01), None
patent: WO 01 62233 (2001-08-01), None
patent: WO 02 085894 (2002-10-01), None
patent: WO 03 088963 (2003-10-01), None
Ulrich Rose, 1990, Journal of Heterocyclic Chemistry, “5-Oxo-1,4-dihydroindenopyridine: . . . ”, 27(2):237-42.
Copy of PCT International Search Report for Appln No. PCT/US02/11823 dated Aug. 27, 2002.
Afsah, E.M. et al.: “Introduction of some pharmaceuticially active heterocycles into the benzylic moiety of 2-benzyl-1,3-indandione”; Pharmazie 45 (1990), H.4, pp. 255-257.
Ascherio, A. et al: “Prospective Study of Caffeine Consumption and Risk of Parkinson's Diesease in Men and Women”; Annals of Neurology, 2001, 50, pp. 56-63.
Bocker, R.H. et al.: “Oxidation of 4-Aryl-and 4-Alkyl-Substituted 2,6-Dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by Human Liver Microsomes and Immunochemical Evidence for the Involvement of a Form of Cytochrome P-450”; J. Med. Chem. 1986, 29, pp. 1596-1603.
Bradley, G. et al.: “2,3-Dihydroquinolin-4(1H)-ones. Part I. Halogen-substituted 2,3-Dihydroquinolin-4(1H)-ones and their 1-(2-Acylethyl) Derivatives”; J. Chem. Soc., Perkin Trans. 1, 1972, pp 2019-2023.
Bullington, J.L. et al.: “The Development of NOvel and Selective p561ck Tyrosine Kinase Inhibitors1”; Bioorg. Med. Chem. Lett. 1998, 8, pp. 2489-2494.
Chatterjea, J.N. et al.; “Synthesis in the 4-Azafluorene Group. Part III”; J. Indian Chem. Soc., vol. LV, 1978, pp. 149-153.
Chen, J.F. et al.: “Neuroprotection of Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease”; J. of Neuroscience, 2001, vol. 21 RC143, pp. 1-6.
Chen, W. et al.: “A Colorimetric Assay for Measuring Activation of Gs-Gq-Coupled Signaling Pathways”; Analytical Biochemistry, 1995, 226, pp. 349-354.
Ferre, S. et al.: “Stimulation of high-affinity adenosine A2receptors decreases the affinity of dopamine D2receptors in rat striatal membranes”; Proceedings of the Nat'l Academy of Sciences of the USA, 1991, 88, pp. 7238-7241.
Fink, J.S. et al.: “Molecular cloning of the rat A2adenosine receptor: selective co-expression with D2dopamine receptors in rat striatum”; Molecular Brain Research, 14 (1992), pp. 186-195.
Gessi, S. et al.: “A2Aadenosine receptors in human peripheral blood cells”; British J. of Pharm., 2000, 129, pp. 2-11.
Gorlitzer, K. et al.: “Indeno[1,2-b]pyridin-4-yl-amine3”; Pharmazie 52 (1997) 7, pp. 504-510.
Ikeda, K. et al.: “Neuroprotection by adenosine A2Areceptor blockade in experimental models of Parkinson's disease”; J. of Neurochemistry, 2002, 80, pp. 262-270.
Impagnatiello, F. et al.: “Adenosine receptors in neurological disorders”; Emerging Therapeutic Targets, 2000, 4, pp. 635-664.
Jursic, B.S. et al.: “A Simple Preparation of Amides from Acids and Amines by Heating of their Mixture”; Synthetic Comm. 1993, 23, pp. 2761-2770.
Kobayashi, T. et al: “Novel 2-Amino-1,4-dihydropyridine Calcium Antagonists. I. Synthesis and Antihypertensive Effects of 2-Amio-1,4-dihydropyridine Derivatives Having Nitroxyalkoxycarbonyl Groups at 3- and/or 5-Position”; Chem. Pharm. Bull. 1995, 43, pp. 788-796.
Li, L. et al.: “CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation”; Science, 1999, vol. 283, pp. 848-851.
Lusis, V. et al.: “Synthesis and Isomerization of 1H-4,4a,5,9b-Tetrahydroindeno-[1,2-b]pyridines”; Tetrahedron, 1991, vol. 47, No. 35, pp. 7429-7436.
Mally, J. et al.: “Efficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placebo and propranolol”; J. of the Neurological Sciences, 1995, 132, pp. 129-132.
Martinez, A. et al.: “Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides: First Phosphodiesterase 7 Inhibitors”; J. Med. Chem. 2000, 43, pp. 683-689.
Ogawa, T. et al.: Synthesis and Configurational Assignment of Methyl 3-Nitrooxypropyl 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate; J. Chem. Soc. Perkin Trans 1, 1993, pp. 525-528.
Omuaru, V.O.T.: “Reactions of cyclic anhydrides with aromatic primary amines: Part 3—Synthesis of novel 3-(N-arylcarbamoyl)-and 3-(N-naphthylcarbamoyl)carboxylic acids”; Indian J. of Chem., 1998, vol. 37B pp. 814-816.
Petrow, V. et al.: “New Syntheses of Heterocyclic Compounds. Part X. 4-Azafluorenones”; JCS, 1949, pp. 2134-2139.
Reddy, A.S. et al.: “A convenient method for the preparation of hydroxamic acids”; Tetrahedron Letters 41 (2000), pp. 6285-6288.
Rose, U.: “5-Oxo-1,4-dihydroindenopyridines: Calcium Modulators with Partial Calcium Agonistic Activity”; J. Heterocyclic Chem., 27, (1990), pp. 237-242.
Rosin, D.L. et al.: “Immunohistochemical Localization of Adenosine A2AReceptors in the Rat Central Nervous System”; The J. of Comparative Neurology, 1998, 401, pp. 163-186.
Salim, H. et al.: “Activation of Adenosine A1and A2AReceptors Modulates Dopamine D2Receptor-Induced Responses in Stably Transfected Human Neuroblastoma Cells”; J. of Neurochemistry, 2000, 74, pp. 432-439.
Sausin'sh, A. et al.: “Methods for the Synthesis of 4-Pyrazolyl- and 4-Pyridyl-5-Oxo-1,4,5,7-Tetrahydrofuro[3,4-b]Pyridines”; Chem. of Heterocyclic Compounds, vol. 31, No. 7, 1995, pp. 841-846.
Stiles, G. et al.: “Adenosine Receptors”; The J. of Biological Chem., 1992, vol. 267 No. 10, pp. 6451-6454.
Vanden Eynde, JJ. et al.: “Old Reagents, New Results: Aromatization of Hantzsch 1,4-Dihydropyridines with Manganese Dioxide and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone.”; Tetrahedron, 1995, vol. 51, No. 23, pp. 6511-6516.
Varani, K. et al.: “Pharmacological and biochemical characterization of purified A2aadenosine receptors in human platelet membranes by [3H]-CGS 21680 binding”; British J. of Pharmacology, 1996, 117, pp. 1693-1701.
Vigante, B. et al.: Latv. PSR Zinat. Akad. Vestis, Kin. Ser. 1980, pp. 707-715.
Vigante, B.A. et al.: “Infrared Absorption of 4,5-Dihydroindeno[1,2-b]Pyridines”; Chem. Het. Compounds, 25(5) 1989, pp. 524-527.
Weissman, S.A. et al.: “Efficient Synthesis of N-Arylpiperazinones via a Selective Intramolecular Mitsunobu Cyclodehydration”; Tetrehedron Lett. 1998, 39, pp. 7459-7462.
Zandersons, A.Z. et al.: Synthesis of 5-Oxoindeno[1,2-b]Pyridinium Salts; Chem. Het. Compounds 22(1), 1986, pp. 73-76.
Zimmer, H. et al.: Substituted y-Lactones. 28.13-(Phenylmethylene)2-3,4(3H,5H)-furandiones.; J. Org. Chem. vol. 43, No. 8, 1978, pp. 1541-1544.
Chemical Abstracts, vol. 59, No. 6, Sep. 16, 1963; XP-002211132.
Copy of PCT International Search Report for Appln No. PCT/US02/30825 dated Nov. 25, 2002.
Database CHEMCATS ‘Online’ (Feb. 11, 2002) , Interbioscreen Compound Library: 2002:3027027, XP002220645.
Database CHEMCATS ‘Online’ (Jan. 21, 2002) , Ambinter: Exploratory Library: 2002:2845045, 2002: XP002220646.
Database CHEMCATS ‘Online’ (Jan. 21, 2002) , Ambinter: Exploratory Library: 2002:1552297, XP002220647.
Database CHEMCATS ‘Online’ (Jan. 15, 2002) , Bionet Research: 2001:2494341, 2001:2494321, XP002220648
Averill Kristin M.
Demarest Keith T.
Dodd John H.
Heintzelman Geoffrey R.
Jackson Paul F.
Herridge Peter L.
Mckane Joseph
Ortho-Muniel Pharmaceutical, Inc.
Shiao Robert
LandOfFree
Arylindenopyridines and related therapeutic and prophylactic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylindenopyridines and related therapeutic and prophylactic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylindenopyridines and related therapeutic and prophylactic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3496895